EP300 and prostate carcinoma: investigated the anti-prostate cancer effect of C646, a small molecular inhibitor of p300/CBP catalytic activity, and found that inhibition of p300 catalytic activity leads to induction of caspase-dependent apoptosis and the reduction of cellular proliferation in several androgen-dependent and castration-resistant PCa cells, triggered by a substantiated decrease in AR function and impaired NF-κB signaling through p65 degradation (142).